Title: Casodex (ICI 176,334), a new, non-steroidal anti-androgen. Early clinical results.
Title Abreviation: Horm Res Date of Pub: 1989
Author: Lunglmayr G;
Issue/Part/Supplement: -HEADING- Volume Issue: 32 Suppl 1 Pagination: 77-81
MESH Headings: Acid Phosphatase (ME); Aged; Androgen Antagonists (AD/*TU); Anilides (AD/*TU); Estradiol (BL); FSH (BL); Human; Male; Middle Age; Prostatic Neoplasms (BL/*DT/EN); Testosterone (BL); -RN-;
Journal Title Code: GBI Publication Type: JOURNAL ARTICLE
Date of Entry: 900315N Entry Month: 9005
Country: SWITZERLAND Index Priority: 2
Language: Eng Unique Identifier: 90128935
Unique Identifier: 90128935 ISSN: 0301-0163
Abstract: Following promising results in animal studies, Casodex (ICI 176,334) has been studied in the treatment of patients with advanced prostate cancer. At doses of 10, 30 and 50 mg, the drug was found to be well tolerated, with a moderate effect on sex hormone levels. The 50 mg dose of Casodex (daily) reduced previously elevated acid phosphatase levels by 50% or more in 71% of patients.
Abstract By: Author
Address: Department of Urology, Mistelbach General Infirmary, Austria.

Thinking about a
Transplant?

Transplants are safer and
more effective than ever.

Find a hair loss doctor.
Enter you Zip/Postal Code:

Search

» Sponsors